hC Bio: restoring protein function with tRNA therapies

hC Bio is among a small set of biotechs pioneering tRNAs as a new therapeutic modality to edit proteins and restore their function without the safety concerns of permanently editing the genome.

The technology behind hC Bioscience Inc. is rooted in a 2019 Nature Communications paper from a group led by co-founder Chris Ahern at the University of Iowa. Leslie Williams, who was an executive in residence at the university, told BioCentury she approached Ahern after reading the paper to argue “this could be a company.”...